Australia's largest stock trading and investment forum Australia's #1 stock forum

SP1

Click for more information

0.00%

$1.07 southern cross payments ltd

$553 * 1.69 = $934k for Mar q $934 * 1.69 = $1,578k for June q...

First 21 Last

Share
Profile

Follow
CaptainBarnacles

11,216 Posts.

701

22/01/18

19:50

Post #: 30479845
Share

Originally posted by Transplant ↑

At 69% compounding Q on Q you would need 3 quarters to get over $2.5m ( $2.67m)
To achieve $2.5m in the next 2 quarters you would need 113% compounding Q on Q.

Not impossible to get the Class A shares, but the dilution risk which might be keeping a few away at the moment is overdone in my view.

Interestingly at 69% compounding in 2 quarters the revenue will be $1.58m and very close to break even with the burn rate.

40% compounding in 3 quarters the revenue will be $1.52m and very close to break even with the burn rate.

So my view is:
1. Management miss out on the class A, B & C shares and the share price adjusts up.
2. In 3 quarters (conservatively) we are cashflow neutral and the shares price adjust up.

270 days to go.

Expand

$553 * 1.69 = $934k for Mar q
$934 * 1.69 = $1,578k for June q
$934k + 1578k = $2,512k = $5m run rate = bingo at 69%

Last edited by CaptainBarnacles: 22/01/18

ISX Price at posting: 16.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 17 more messages in this thread...

First 21 Last

Add SP1 (ASX) to my watchlist